Click for best price
Oral Drugs for Benign Prostatic Hyperplasia Market Size, Share 2023
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a mans life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
This report contains market size and forecasts of Oral Drugs for Benign Prostatic Hyperplasia in global, including the following market information:
The global Oral Drugs for Benign Prostatic Hyperplasia market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Alpha Blockers Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Oral Drugs for Benign Prostatic Hyperplasia include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Viatris, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Oral Drugs for Benign Prostatic Hyperplasia manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Type, 2022 (%)
- Alpha Blockers
- 5-alpha Reductase Inhibitors
- Others
Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Application, 2022 (%)
- Hospitals
- Drugstores
- Others
Global Oral Drugs for Benign Prostatic Hyperplasia Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues share in global market, 2022 (%)
- Key companies Oral Drugs for Benign Prostatic Hyperplasia sales in global market, 2018-2023 (Estimated), (K Units)
- Key companies Oral Drugs for Benign Prostatic Hyperplasia sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Eli Lilly
- GlaxoSmithKline
- Astellas Pharma
- Sanofi
- Pfizer
- Abbott
- Allergan
- TEVA
- Viatris
- Novartis
- Merck
| Report Attributes |
Report Details |
| Report Title |
Oral Drugs for Benign Prostatic Hyperplasia Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
73 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Oral Drugs for Benign Prostatic Hyperplasia Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oral Drugs for Benign Prostatic Hyperplasia Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oral Drugs for Benign Prostatic Hyperplasia Overall Market Size
2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Market Size: 2022 VS 2030
2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Oral Drugs for Benign Prostatic Hyperplasia Sales: 2018-2030
3 Company Landscape
3.1 Top Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market
3.2 Top Global Oral Drugs for Benign Prostatic Hyperplasia Companies Ranked by Revenue
3.3 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Companies
3.4 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Companies
3.5 Global Oral Drugs for Benign Prostatic Hyperplasia Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Oral Drugs for Benign Prostatic Hyperplasia Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Product Type
3.8 Tier 1, Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market
3.8.1 List of Global Tier 1 Oral Drugs for Benign Prostatic Hyperplasia Companies
3.8.2 List of Global Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size Markets, 2022 & 2030
4.1.2 Alpha Blockers
4.1.3 5-alpha Reductase Inhibitors
4.1.4 Others
4.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
4.2.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2023
4.2.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2023-2030
4.2.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
4.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
4.3.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2023
4.3.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2023-2030
4.3.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
4.4 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Price (Manufacturers Selling Prices), 2018-2030
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Drugstores
5.1.4 Others
5.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
5.2.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2023
5.2.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2023-2030
5.2.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
5.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
5.3.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2023
5.3.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2023-2030
5.3.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
5.4 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2022 & 2030
6.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
6.2.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2023
6.2.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2023-2030
6.2.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
6.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
6.3.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2023
6.3.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2023-2030
6.3.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2030
6.4.2 By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2030
6.4.3 US Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.4.4 Canada Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.4.5 Mexico Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2030
6.5.2 By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2030
6.5.3 Germany Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.5.4 France Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.5.5 U.K. Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.5.6 Italy Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.5.7 Russia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.5.8 Nordic Countries Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.5.9 Benelux Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2030
6.6.2 By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2030
6.6.3 China Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.6.4 Japan Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.6.5 South Korea Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.6.6 Southeast Asia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.6.7 India Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2030
6.7.2 By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2030
6.7.3 Brazil Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.7.4 Argentina Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2030
6.8.3 Turkey Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.8.4 Israel Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.8.5 Saudi Arabia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
6.8.6 UAE Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Corporate Summary
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.1.4 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.1.5 Eli Lilly Key News
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Corporate Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.2.4 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.2.5 GlaxoSmithKline Key News
7.3 Astellas Pharma
7.3.1 Astellas Pharma Corporate Summary
7.3.2 Astellas Pharma Business Overview
7.3.3 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.3.4 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.3.5 Astellas Pharma Key News
7.4 Sanofi
7.4.1 Sanofi Corporate Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.4.4 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.4.5 Sanofi Key News
7.5 Pfizer
7.5.1 Pfizer Corporate Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.5.4 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.5.5 Pfizer Key News
7.6 Abbott
7.6.1 Abbott Corporate Summary
7.6.2 Abbott Business Overview
7.6.3 Abbott Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.6.4 Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.6.5 Abbott Key News
7.7 Allergan
7.7.1 Allergan Corporate Summary
7.7.2 Allergan Business Overview
7.7.3 Allergan Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.7.4 Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.7.5 Allergan Key News
7.8 TEVA
7.8.1 TEVA Corporate Summary
7.8.2 TEVA Business Overview
7.8.3 TEVA Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.8.4 TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.8.5 TEVA Key News
7.9 Viatris
7.9.1 Viatris Corporate Summary
7.9.2 Viatris Business Overview
7.9.3 Viatris Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.9.4 Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.9.5 Viatris Key News
7.10 Novartis
7.10.1 Novartis Corporate Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.10.4 Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.10.5 Novartis Key News
7.11 Merck
7.11.1 Merck Corporate Summary
7.11.2 Merck Oral Drugs for Benign Prostatic Hyperplasia Business Overview
7.11.3 Merck Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.11.4 Merck Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.11.5 Merck Key News
8 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity, Analysis
8.1 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity, 2018-2030
8.2 Oral Drugs for Benign Prostatic Hyperplasia Production Capacity of Key Manufacturers in Global Market
8.3 Global Oral Drugs for Benign Prostatic Hyperplasia Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Oral Drugs for Benign Prostatic Hyperplasia Supply Chain Analysis
10.1 Oral Drugs for Benign Prostatic Hyperplasia Industry Value Chain
10.2 Oral Drugs for Benign Prostatic Hyperplasia Upstream Market
10.3 Oral Drugs for Benign Prostatic Hyperplasia Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Oral Drugs for Benign Prostatic Hyperplasia Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Oral Drugs for Benign Prostatic Hyperplasia in Global Market
Table 2. Top Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Share by Companies, 2018-2023
Table 5. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Companies, (K Units), 2018-2023
Table 6. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Product Type
Table 9. List of Global Tier 1 Oral Drugs for Benign Prostatic Hyperplasia Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2023-2030
Table 14. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2018-2023
Table 15. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2023-2030
Table 16. By Application ? Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2023-2030
Table 19. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2018-2023
Table 20. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2023-2030
Table 21. By Region ? Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2023-2030
Table 24. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2018-2023
Table 25. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2023-2030
Table 26. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2023-2030
Table 28. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2018-2023
Table 29. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2023-2030
Table 30. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2023-2030
Table 32. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2018-2023
Table 33. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2023-2030
Table 34. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2023-2030
Table 36. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2018-2023
Table 37. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2023-2030
Table 38. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2023-2030
Table 40. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2018-2023
Table 41. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2023-2030
Table 42. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2023-2030
Table 44. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2023-2030
Table 46. Eli Lilly Corporate Summary
Table 47. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 48. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. GlaxoSmithKline Corporate Summary
Table 50. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 51. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 52. Astellas Pharma Corporate Summary
Table 53. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 54. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 55. Sanofi Corporate Summary
Table 56. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 57. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 58. Pfizer Corporate Summary
Table 59. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 60. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Abbott Corporate Summary
Table 62. Abbott Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 63. Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 64. Allergan Corporate Summary
Table 65. Allergan Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 66. Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 67. TEVA Corporate Summary
Table 68. TEVA Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 69. TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 70. Viatris Corporate Summary
Table 71. Viatris Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 72. Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Novartis Corporate Summary
Table 74. Novartis Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 75. Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 76. Merck Corporate Summary
Table 77. Merck Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 78. Merck Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 79. Oral Drugs for Benign Prostatic Hyperplasia Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 80. Global Oral Drugs for Benign Prostatic Hyperplasia Capacity Market Share of Key Manufacturers, 2021-2023
Table 81. Global Oral Drugs for Benign Prostatic Hyperplasia Production by Region, 2018-2023 (K Units)
Table 82. Global Oral Drugs for Benign Prostatic Hyperplasia Production by Region, 2023-2030 (K Units)
Table 83. Oral Drugs for Benign Prostatic Hyperplasia Market Opportunities & Trends in Global Market
Table 84. Oral Drugs for Benign Prostatic Hyperplasia Market Drivers in Global Market
Table 85. Oral Drugs for Benign Prostatic Hyperplasia Market Restraints in Global Market
Table 86. Oral Drugs for Benign Prostatic Hyperplasia Raw Materials
Table 87. Oral Drugs for Benign Prostatic Hyperplasia Raw Materials Suppliers in Global Market
Table 88. Typical Oral Drugs for Benign Prostatic Hyperplasia Downstream
Table 89. Oral Drugs for Benign Prostatic Hyperplasia Downstream Clients in Global Market
Table 90. Oral Drugs for Benign Prostatic Hyperplasia Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Oral Drugs for Benign Prostatic Hyperplasia Segment by Type
Figure 2. Oral Drugs for Benign Prostatic Hyperplasia Segment by Application
Figure 3. Global Oral Drugs for Benign Prostatic Hyperplasia Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Oral Drugs for Benign Prostatic Hyperplasia Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2030 (US$, Mn)
Figure 7. Oral Drugs for Benign Prostatic Hyperplasia Sales in Global Market: 2018-2030 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Oral Drugs for Benign Prostatic Hyperplasia Revenue in 2022
Figure 9. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
Figure 10. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
Figure 11. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit), 2018-2030
Figure 12. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
Figure 13. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
Figure 14. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit), 2018-2030
Figure 15. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
Figure 16. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
Figure 17. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
Figure 18. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
Figure 19. US Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 20. Canada Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 21. Mexico Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 22. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
Figure 23. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
Figure 24. Germany Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 25. France Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 26. U.K. Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 27. Italy Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 28. Russia Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 29. Nordic Countries Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 30. Benelux Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 31. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
Figure 32. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
Figure 33. China Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 34. Japan Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 35. South Korea Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 36. Southeast Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 37. India Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 38. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
Figure 39. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
Figure 40. Brazil Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 41. Argentina Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2030
Figure 43. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2030
Figure 44. Turkey Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 45. Israel Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 46. Saudi Arabia Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 47. UAE Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2030
Figure 48. Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity (K Units), 2018-2030
Figure 49. The Percentage of Production Oral Drugs for Benign Prostatic Hyperplasia by Region, 2022 VS 2030
Figure 50. Oral Drugs for Benign Prostatic Hyperplasia Industry Value Chain
Figure 51. Marketing Channels
